- Company
- SGLT2i+DPP4i combos' performance falls short of expectations
- by Kim, Jin-Gu Jan 23, 2024 06:02am
- A large number of 'SGLT-2 inhibitor (SGLT2i)+DPP-4 inhibitor (DPP4i)' combinations entered the market after Korea’s insurance reimbursement was extended to cover ‘SGLT-2 inhibitor + DPP-4 inhibitor’ combinations, however, their sales performance in the first year is falling short of expectations. Of the major products that have been on
- Company
- Will Verzenio secure expansion for early breast cancer?
- by Eo, Yun-Ho Jan 23, 2024 06:02am
- ‘Verzenio’, which faced difficulties in expanding its reimbursement standards last year, is now drawing attention to see if it will pass the review this time. According to industry sources, Lily Korea’s CDK4/6 inhibitor Verzenio (abemaciclib) is expected to be considered for the Health Insurance Review and Assessment Service (HIRA)
- Company
- Sotatercept receives orphan drug designation in Korea
- by Eo, Yun-Ho Jan 22, 2024 05:49am
- Sotatercept, a new drug candidate for pulmonary arterial hypertension (PAH), has been designated an orphan drug in Korea. The Ministry of Food and Drug Safety recently announced the drug’s designation in the first orphan drug designation announcement it made in the new year. Sotatercept, which is being developed by Merck, is being re
- Company
- First oHCM drug Camzyos applies for reimb in Korea
- by Eo, Yun-Ho Jan 22, 2024 05:49am
- The first-ever obstructive hypertrophic cardiomyopathy (oHCM) treatment, ‘Camzyos,’ is being reviewed for reimbursement in Korea. According to industry sources, BMS Korea has recently applied for the reimbursement listing of its new obstructive hypertrophic cardiomyopathy (oHCM) drug Camzyos (mavacamten). Therefore, whether the drug
- Company
- Hemlibra reduces risk of exercise-associated bleeding
- by Lee, Seok-Jun Jan 19, 2024 05:44am
- The research findings, which include data on the physical activities of patients treated with JW Pharmaceutical’s hemophilia A treatment ‘Hemlibra (emicizumab)’ and their safety profile, have been published in the International Journal of Hematology (Int J Hematol). Hemlibra is an innovative new drug that mimics the function of blood
- Company
- Keytruda's reimb for 6 indications will be reviewed
- by Eo, Yun-Ho Jan 19, 2024 05:44am
- The reimbursement challenge for Keytruda continues this year. Although no results have been made, the company seems to be on a steady course in applying for reimbursement. According to industry sources, 6 indications of MSD Korea’s PD-1 inhibitor immuno-oncology drug Keytruda (pembrolizumab) are expected to be submitted to the Health Ins
- Company
- AstraZeneca begins ERP and business unit restructuring
- by Son, Hyung-Min Jan 18, 2024 04:51pm
- AstraZeneca Korea has initiated an early retirement program following the withdrawal of the diabetes treatment Forxiga from the Korean market. The company has stated that it is in discussions with the government to minimize the impact of Forxiga’s withdrawal along with its business unit restructuring. According to the pharmaceutical industr
- Company
- Keytruda approved as 1st-line treatment for gastric cancer
- by Son, Hyung-Min Jan 18, 2024 04:46pm
- Keytruda, a cancer immunotherapy developed by MSD, has been approved as a first-line treatment for gastric cancer in Korea. Keytruda has emerged as a new first-line treatment option, thirteen years after Herceptin (ingredient: trastuzumab) received approval in 2010. On the 16th, MSD hosted a press conference at Lotte Hotel Seoul commenci
- Company
- MA manager files complaint on NHIS official's abuse of power
- by Eo, Yun-Ho Jan 18, 2024 06:07am
- A controversy has arisen over the abuse of power made by an official from the National Health Insurance Service’s Department of Pharmaceutical Benefits. According to industry sources, B, a market access (MA) manager at pharmaceutical company A, filed a civil complaint with the Anti-Corruption & Civil Rights Commission’s e-People page, a
- Company
- Orion bids KRW 548.5 bil to enter the pharma industry
- by Kim, Jin-Gu Jan 17, 2024 05:29am
- The Orion Group has become the largest shareholder of LegoChem Biosciences, a prime new drug developer. With the acquisition of LegoChem, Orion is expected to jump into the pharmaceutical bio-industry in earnest, breaking away from its previous passive activities such as signing a memorandum of understandings, making indirect investments
